

FINANCIAL STATEMENTS
AS AT 31 OCTOBER 2025

OMEGA DIAGNOSTICS (IRELAND) LIMITED

Omega Diagnostics (Ireland) Limited
Financial statements as at 31 October 2025

Contents

Directors' Responsibilities Statement	2
Balance Sheet	3
Statement of Changes in Equity	4
Notes to the Financial Statements	5

Directors' Responsibilities Statement

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors' Responsibilities Statement accompanying those financial statements.

Company law requires the directors to prepare financial statements for each financial year. Under that law, they have elected to prepare the financial statements in accordance with FRS 105, the Financial Reporting Standard applicable to the Micro-entities Regime (FRS 105).

As such the directors are responsible for preparing financial statements in accordance with the provisions of the Companies Act 2014 with which the company is obliged to comply, including the appropriate use of the going concern basis of accounting, which is consistent with those requirements, and having availed of the exemptions to which the company is entitled by virtue of qualifying for the micro company's regime and FRS105. Thereby, the financial statements are presumed, in law, to give a true and fair view without any consideration of any other circumstances, factors, accounting principles or disclosures.

The directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the company and enable them to ensure that the financial statements comply with the Companies Act 2014. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities.

Omega Diagnostics (Ireland) Limited
Abridged financial statements as at 31 October 2025

Balance Sheet
as at 31 October 2025

	2025	2024
	€	€
Fixed assets		
Tangible assets	-	-
Current assets		
Stocks	53,069	37,827
Debtors	83,138	72,333
Cash at bank	367,197	301,970
	<u>503,404</u>	<u>412,130</u>
Creditors (amounts falling due within one year)	<u>(83,010)</u>	<u>(91,893)</u>
Net current assets	<u>420,394</u>	<u>320,237</u>
Net assets	<u>420,394</u>	<u>320,237</u>
Capital and reserves		
Called up share capital	66	66
Capital redemption reserve	61	61
Profit and loss account	<u>420,267</u>	<u>320,110</u>
	<u>420,394</u>	<u>320,237</u>

We, as Directors of Omega Diagnostics (Ireland) Limited, state that:

1. the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
2. the company is availing itself of the exemption on the grounds that the conditions specified in s.358 are satisfied,
3. the shareholders of the company have not served a notice on the company under s.334(1) in accordance with s.334(2),
4. we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare Financial Statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to Financial Statements so far as they are applicable to the company,
5. the company has relied on the specified exemption contained in s.352 Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged Financial Statements have been properly prepared in accordance with s.353 Companies Act 2014.

Approved by the board of directors and signed on its behalf by:

Vincent Wilson
Director
Date: 25 January 2026

Omega Diagnostics (Ireland) Limited
Abridged financial statements as at 31 October 2025

Statement of Changes in Equity

	Called up Share Capital €	Other un- denominated Capital €	Profit and Loss Account €	Total €
31-Oct-24	66	61	320,110	320,237
Movements during the year	-	-	100,157	100,157
31-Oct-25	66	61	420,267	420,394

Omega Diagnostics (Ireland) Limited

Abridged financial statements as at 31 October 2025

Notes to the Financial Statements

1. General information

The company is a private company limited by shares, registered in Ireland. The address of the registered office is Omega Diagnostics (Ireland) Limited, Unit 28a Bullford Business Campus, Newtown Road, Kilcoole, Co Wicklow.

2. Accounting policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements:

a) Basis of preparation

The financial statements have been prepared on a going concern basis and in accordance with the historic cost convention. An assumption has been made that a satisfactory outcome will be reached with the Revenue Commissioners in relation to outstanding taxes and interest thereon. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and Accounting Standards issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants in Ireland for periods commencing before 1 January 2015.

b) Cash flow statement

The company meets the size criteria for a small company set by the Companies Act, 2014 and therefore, in accordance with the exemption contained in FRS 1 (revised 1996) Cash Flow Statements, it has not prepared a cash flow statement.

c) Turnover

Turnover represents net sales to customers excludes VAT and derives from the provision of goods and services falling within the company's ordinary activities. Turnover on the sale of goods is recognised when the company has transferred the significant risks and rewards of ownership in the goods, which usually takes place when the goods are physically delivered to the buyer.

d) Tangible Fixed Assets and Depreciation

Tangible fixed assets are stated at historic cost less accumulated depreciation. Cost represents those costs that are directly attributable to bringing the asset into working condition for its intended use should be included in its measurement and comprise its purchase price (after deducting any trade discounts and rebates) and any costs directly attributable to bringing it into working condition for its intended use.

The charge for depreciation is calculated to write down the cost of assets to their estimated residual values by equal annual instalments over their expected useful lives which are as follows:

Fixtures fittings and equipment	25% to 33%
---------------------------------	------------

e) Stocks and work in progress

Stocks are stated at the lower of cost and net realisable value using the first in first out method. In the case of finished goods and work in progress, cost is defined as the aggregate cost of raw materials, direct labour and the attributable proportion of direct production overheads.

Net realisable value is based on normal selling price, less further costs expected to be incurred to completion and disposal.

f) Foreign currencies

Transactions in foreign currencies are recorded at the rate ruling at the date of the transactions or at a contracted rate. The resulting monetary assets and liabilities are translated at the balance sheet rate or the contracted rate and the exchange differences are dealt with in the profit and loss account.

g) Taxation

The yearly charge for taxation is based on the tax-adjusted profit for the financial year and is calculated with reference to the tax rates enacted or substantially enacted at the financial year-end date.

Omega Diagnostics (Ireland) Limited
Abridged financial statements as at 31 October 2025

3. Debtors

	2025	2024
	€	€
Trade debtors	<u>83,138</u>	<u>72,333</u>
	<u>83,138</u>	<u>72,333</u>

4. Creditors: amounts falling due within one year

	2025	2024
	€	€
Trade creditors	2,257	7,838
Accruals	65,608	65,515
Other creditors including tax & social insurance	<u>15,145</u>	<u>18,540</u>
	<u>83,010</u>	<u>91,893</u>

The repayment terms of trade creditors vary between on-demand and sixty days. Trade creditors do not attract interest. Tax and social insurance are subject to the terms of the relevant legislation. Interest accrues on late payments at the rate of 2.5% per month. No interest was due at the financial year-end date. The terms of the accruals are based on the underlying contracts.

5. Approval of financial statements

The directors approved the financial statements and authorised them for issue on 25 January 2026.